Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 12 of 15

 
 

Jazz Pharmaceuticals (NASDAQ:JAZZ)

Consensus Rating
Moderate Buy
Rating Score
2.8
Ratings Breakdown
12 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$175.00 (40.8% Upside)

About Jazz Pharmaceuticals

Jazz Pharmaceuticals logoJazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
11/7/2024TD CowenLower Price TargetBuy ➝ Buy$200.00 ➝ $195.00
11/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$207.00 ➝ $207.00
10/23/2024Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$175.00 ➝ $179.00
10/4/2024Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$174.00 ➝ $175.00
9/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$205.00 ➝ $205.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00 ➝ $140.00
8/19/2024JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$190.00 ➝ $202.00
8/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00 ➝ $140.00
8/1/2024Piper SandlerLower Price TargetOverweight ➝ Overweight$188.00 ➝ $166.00
8/1/2024Royal Bank of CanadaLower Price TargetOutperform ➝ Outperform$175.00 ➝ $174.00
 

This company will win the AI race (Ad)

Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.